Research library

Key finding

Ipamorelin stimulated potent growth-hormone release in rat and swine models while showing markedly less ACTH and cortisol release than comparator secretagogues.

Key finding

In healthy volunteers, ipamorelin produced dose-related growth-hormone responses that were captured by a pharmacokinetic-pharmacodynamic model across the tested dose range.

Key finding

Repeated ipamorelin administration increased longitudinal bone growth in rats, consistent with its selective growth-hormone-releasing activity.

Key finding

In adult female rats, ipamorelin increased bone mineral content, supporting a growth-hormone-mediated effect on bone remodelling.

Key finding

In a randomized postoperative study, ipamorelin was well tolerated but did not significantly shorten recovery from postoperative ileus after bowel resection.

Key finding

The authors reported that ipamorelin accelerates gastric emptying in a rodent model of postoperative ileus through the stimulation of gastric contractility by activating a ghrelin receptor-mediated mechanism involving cholinergic excitatory neurons.

Key finding

Ghrelin and ghrelin mimetics stimulate appetite and enhance gastric motility.

Key finding

Growth hormone (GH) is secreted in the anterior pituitary gland by the somatotroph cells.

Key finding

Growth hormone secretagogues (GHSs) stimulate growth hormone (GH) secretion, which is lipolytic.

Key finding

Growth hormone releasing peptides (GHRPs) stimulate secretion of endogenous growth hormone and are listed on the World Anti-Doping Agency (WADA) Prohibited List.

Key finding

NN703 is a novel orally active GH secretagogue (GHS) derived from ipamorelin.

Key finding

The present study was undertaken to study the growth hormone-releasing properties and growth-promoting effect of a GH secretagogue ipamorelin (IPA) in rats given the synthetic glucocorticoid methylprednisolone (MP).

Key finding

A new series of GH secretagogues derived from ipamorelin is described.

Key finding

Male hypogonadism is an increasingly prevalent clinical condition that affects patients' quality of life and overall health.

Key finding

The study reports that anamorelin (10 µg) administered intracerebroventricularly reduced cisplatin-induced acute emesis by 60 % but did not affect delayed emesis.

Key finding

The discovery of the growth hormone secretagogues (GHS) and the reverse pharmacology leading to the discovery of GHS receptor which enabled the identification of ghrelin as the natural ligand for the receptor have opened a new horizon in growth hormone (GH) physiology, pathophysiology, and therapeutics.

Key finding

Realizing the reported misuse of human growth hormone (GH), investigation of a safe alternative mechanism for increasing endogenous GH is needed.

Key finding

Further work is needed to better understand the long-term impact of GHSs on human anatomy and physiology and more specifically in the context of a diversity of clinical scenarios.

Key finding

Small synthetic molecules called growth-hormone secretagogues (GHSs) stimulate the release of growth hormone (GH) from the pituitary.

Key finding

Ghrelin and the growth hormone secretagogue receptor 1a (GHS-R1a) are important targets for disorders related to energy balance and metabolic regulation.